ArticleThoracic cancer2022

Retrospective analysis of independent predictors of progression-free survival in patients with EGFR mutation-positive advanced non-small cell lung cancer receiving first-line osimertinib.

Shuhei Teranishi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.